Rate of Post-Fertilization Mitotic Activity Predicts Embryonic Competence via Next Generation Sequencing: An Analysis of 39,301 Cleavage Stage Embryos

Jenna Friedenthal¹, Stephanie Pan¹, Dmitry Gounko², Christine Briton-Jones¹, Joseph Lee², Alan Copperman¹

¹ Department of Obstetrics, Gynecology, and Reproductive Science. Icahn School of Medicine at Mount Sinai. New York, NY 10029, USA
² Reproductive Medicine Associates of New York. New York, NY 10022, USA

This material was presented as an oral presentation at the 75th American Society for Reproductive Medicine Scientific Congress and Expo (October 2019)

ABSTRACT
Objective: To investigate the association between cleavage stage development, embryonic competence, and euploidy in patients undergoing in vitro fertilization (IVF) with subsequent next generation sequencing.

Methods: The retrospective cohort study included patients at an academic fertility center who underwent IVF with at least one cleavage stage embryo from 2016 to 2019. Embryos were analyzed as slow (<6 cells), intermediate (6-8 cells), or fast (>8 cells); day 3 cell count was also analyzed as a continuous variable. Primary outcomes were blastulation rate, biopsied blastocyst rate, and euploid rate. Odds of blastulation, biopsy, and euploidy were also calculated. Additionally, we modeled the predicted probability of an embryo reaching blastulation, biopsy, and euploidy based on cleavage stage development.

Results: When compared with intermediate and slow cohorts, fast cleaving embryos had significantly higher rates of blastulation (82.70% vs. 75.13% vs. 42.48%), biopsy (55.04% vs. 44.00% vs. 14.98%), and euploidy (50.65% vs. 47.93% vs. 48.05%). After adjustment for covariates, there was a significant association between cleavage stage development and odds of blastulation (OR 1.38, 95% CI 1.29-1.48), biopsy (OR 1.42, 95% CI 1.34-1.51), and euploidy (OR 1.08, 95% CI 1.01-1.17). Finally, we observed significant associations between cleavage stage development and predicted probability of reaching blastulation (OR 1.29, 95% CI 1.27-1.32), biopsy (OR 1.24, 95% CI 1.22-1.26), and euploidy (OR 1.02, 95% CI 1.01-1.04).

Conclusions: Cleavage stage embryos with greater mitotic activity perform as well as or better than intermediate or slower cleaving embryos. Rapidly cleaving embryos have high rates of euploidy and significant clinical potential.

Keywords: next generation sequencing, cleavage stage embryos, rapid cell division, preimplantation genetic testing, euploidy

INTRODUCTION

The ability to define markers of embryonic competence in order to enhance cycle outcome success is one of the most important aspects of assisted reproductive technology (ART) treatment. Previous research has suggested that early development to the cleavage stage may be a strong predictor of outcomes (Bos-Mikich et al., 2001). For years, rapid cell division of the early stage embryo was thought to be "chaotic," and cleavage stage embryos with more than eight cells were thought to have poor developmental potential (Alikani et al., 2000). However, data is conflicting, as recent published work has demonstrated that rapidly dividing cleavage stage embryos have a high likelihood of blastulation (Luna et al., 2008; Lee et al., 2012).

Additionally, it is well established that the majority of first trimester losses are due to embryonic aneuploidy (Petracchi et al., 2009). With the development of extended culture to blastocyst and the ability to perform trophectoderm (TE) biopsy, pre-implantation genetic testing for aneuploidy (PGT-A) has become the modern standard to distinguish chromosomally normal and abnormal embryos, with the goal of improving pregnancy rates and reducing miscarriage rates. Prior work has attempted to correlate cleavage stage development with embryonic aneuploidy. However, these studies used older technologies (e.g. fluorescence in situ hybridization (FISH), SNP array, and/or array comparative genomic hybridization, or aCGH) (Luna et al., 2008; Campbell et al., 2013; Anderson et al., 2004; Magli et al., 1998). To date, there has yet to be a study correlating cleavage stage cell division with ploidy status as diagnosed by next generation sequencing (NGS). NGS has emerged as the best-in-class platform for PGT-A and has become increasingly popular due to its ability to perform high throughput sequencing with decreased cost (Munné & Wells, 2017). NGS is also able to better identify segmental aneuploidies, polyplody, unbalanced translocations, and mosaicism as compared with other PGT-A platforms (Maxwell et al., 2016; Friedenthal et al., 2018). Thus, the goal of our study was to assess the relationship between rate of cleavage stage development, embryonic competence, and euploid rate as diagnosed by NGS.

MATERIALS AND METHODS

Study design and patient population
This study was approved by an academic Institutional Review Board (IRB# 18-00452). The retrospective cohort study included patients from a single academic center who underwent controlled ovarian stimulation, in vitro fertilization (IVF) with intracytoplasmic sperm injection (ICSI), and had at least one embryo that reached cleavage stage from 2016 to 2019. Exclusion criteria included cases involving multiple biopsies on the same blastocyst, patients who utilized donor oocytes, or patients with incomplete demographic data. Additionally, as per our center's standard operating procedure, embryos with ≤ 3 cells on day 3 are discarded and were excluded from this study's analysis.

Demographic baseline clinical data were collected, including patient age, body mass index (BMI), and AMH level (ng/mL). Percent embryo fragmentation and cell count were evaluated on day 3 of development. Additionally, the time of embryo assessment was computed as the duration (in hours) between the completion of ICSI on day 0 and the time of assessment on day 3 by our embryologists. The mean duration in culture was determined over the study population and used to calculate an adjusted cleavage stage cell count as described in our statistical analysis.

Stimulation protocol and laboratory procedures
Controlled ovarian stimulation was performed as described previously (Sekhon et al., 2018). When at least two
follies reached ≥18mm in diameter, trigger of final maturation was performed using either recombinant HCG alone, or 40 IU of a GnRH agonist in combination with 1000IU HCG. Subsequently, patients underwent oocyte retrieval under transvaginal ultrasonographic guidance. All oocytes that reached the metaphase II stage (MII) underwent ICSI approximately 4-6 hours after retrieval. Those embryos in which fertilization had been confirmed on day 1 of development were then evaluated on day 3 for cleavage stage development. Embryos were then cultured to the blastocyst stage and subsequently underwent assisted hatching. Blastocyst TE biopsies were then performed on day 5, 6, or 7 of development if an embryo reached a morphologic grade of ≥4CC (Modified Gardner score). Detailed description of our embryo culture and TE biopsy techniques have been described elsewhere (Hernandez-Nieto et al., 2019). PGT-A was performed was performed using NGS at partnering genetics laboratories.

Outcomes
Our primary outcome was euploid rate (ER), calculated for each cycle as the number of embryos diagnosed as euploid by trophectoderm (TE) biopsy for NGS divided by the total number of blastocysts that were biopsied. All embryos were screened using NGS for PGT-A. Secondary outcomes included blastulation rate and biopsy blastocyst rate. Blastulation rate was calculated as the number of embryos that developed to the blastocyst stage divided by the number of cleavage stage embryos. Biopsied blastocyst rate was calculated as the number of blastocysts that were biopsied for PGT-A divided by the number of cleavage stage embryos. Additionally, we modeled the predicted probability of an embryo reaching blastulation, the predicted probability of an embryo being biopsied, and the predicted probability of an embryo being euploid based on day 3 cell count as described in our statistical analysis.

Statistical analysis
Cleavage stage cell division was analyzed as both a categorical and a continuous variable. As a categorical variable, embryos that reached the cleavage stage were divided into three cohorts: slow, intermediate, and fast. Adjusted cleavage stage cell counts were calculated by determining the mean time in culture (m) over the sample population and scaling each cell count by the ratio mean/time in culture. Slow growing cleavage stage embryos were defined as having < 6 cells. Intermediate developing cleavage stage embryos were defined as having 6-8 cells. Fast developing cleavage stage embryos were defined as embryos with > 8 cells. Demographics and clinical outcomes were described and compared between cleavage stage cohorts using linear and logistic generalized estimating equation (GEE) regression models. In adjusted analyses, the association between cleavage stage cell division and our outcomes were analyzed using logistic multivariable generalized estimating equation (GEE) regression models to account for within-correlation at the patient and cycle level, using the intermediate group as the reference group. Clinically relevant covariates in the model included patient age, body mass index (BMI), anti-Müllerian hormone (AMH) levels, and percent embryo fragmentation. Patient age was grouped as follows according to the Society for Assisted Reproductive Technology (SART): < 35, 35 – 37, 38 – 40, 41 – 42, and > 42 years old. Embryo fragmentation was categorized as follows: <10%, 10-20%, and >20%.

We repeated the analysis of rate of cleavage stage cell division with our primary and secondary outcomes, but treated cell count as a continuous variable. Univariate and multivariable logistic GEE models were performed. Model estimates were utilized to graphically illustrate the predicted probability of progressing to blastocyst, reaching trophectoderm biopsy, and euploidy. Predicted probabilities were stratified by age groups with BMI and AMH fixed at the patient sample mean and percent embryo fragmentation at the < 10% category. Results were reported as odds ratios (ORs) with 95% confidence intervals (95% CIs). A value of p<0.05 was considered statistically significant. Statistical analyses were performed with SAS version 9.4 (SAS Institute Inc, Cary, NC).

RESULTS
A total of 39,301 cleavage stage embryos from 3,522 patients were assessed in the study and met inclusion criteria. Demographics and clinical characteristics are presented and stratified by cleavage stage development (e.g. slow, intermediate, fast) in Table 1. The average patient age was higher in the slow developing cohort compared to intermediate and fast cohorts (36.67±4.48 vs. 36.67±4.58 vs. 36.23±4.67, p<0.0001). AMH, in contrast, was lower in patients with slow developing embryos compared to the other groups. Further, slower developing embryos had, on average, a higher proportion of fragmentation relative to the other groups (8.24±10.65 vs. 4.15±6.93 vs. 2.70±5.08, p<0.0001).

In the adjusted multivariable analysis (Table 2), we observed that fast growing embryos had significantly higher odds of reaching blastulation compared to intermediate or slow developing embryos (p<0.0001). Additionally, fast developing embryos had significantly higher odds of reaching trophectoderm biopsy after adjusting for confounders (p<0.0001). Finally, fast growing embryos were more likely to be diagnosed as euploid by NGS compared to intermediate or slow growing embryos (p=0.03).

On a continuous scale for cleavage stage cell division, the estimates from the adjusted multivariable analysis are

| Table 1. Demographic and clinical data of embryos from patients undergoing IVF-ICSI from 2016 to 2019. |
|-----------------|-------------------|-----------------|-----------------|------------------|
| Slow            | Intermediate      | Fast             | p-value         |
| (n=6,153 embryos) | (n=13,894 embryos) | (n=19,254 embryos) |                  |
| Demographics    |                   |                  |                 |
| Age (years)     | 36.67±4.48        | 36.67±4.58       | 36.23±4.67      | <0.0001          |
| BMI (kg/m²)     | 24.10±4.55        | 24.07±4.43       | 24.10±4.44      | 0.85             |
| AMH (ng/mL)     | 3.81±4.21         | 3.82±4.10        | 4.20±4.80       | 0.002            |
| Embryo Fragmentation (%) | 8.24±10.65 | 4.15±6.93 | 2.70±5.08 | <0.0001 |
| Clinical Outcomes |                   |                  |                 |
| Blastulation Rate | 2,614/6,153 (42.48) | 10,439/13,894 (75.13) | 15,924/19,254 (82.70) | <0.0001 |
| Biopsied Blastocyst Rate | 922/6,153 (14.98) | 6,113/13,894 (44.00) | 10,597/19,254 (55.04) | <0.0001 |
| Euploid Rate    | 443/922 (48.05)   | 2,930/6,113 (47.93) | 5,367/10,597 (50.65) | 0.005            |

JBRA Assist. Reprod. | v.25 | n°4 | Oct-Nov-Dec/ 2021
reported in Table 3. After accounting for patient age, BMI, AMH, and percent embryo fragmentation, we observed a significant association between cleavage stage development and the odds of an embryo reaching blastocyst, being biopsied, and being diagnosed euploid. The odds of an embryo developing to the blastocyst stage was 1.29 times or 29% higher (95% CI 1.27-1.32) for each increase in cell count, controlling for all other covariates. The odds of an embryo reaching biopsy was 1.24 times or 24% higher (95% CI 1.22-1.26) for each increase in cell count, controlling for confounders. Finally, there was a significant association between increasing day 3 cell count and odds of euploidy (p=0.007). The predicted probabilities of a cleavage stage embryo developing to the blastocyst stage, reaching trophectoderm biopsy, and being euploid after accounting for other covariates and for each cell count assessed are illustrated in Figures 1-3, respectively. The predicted probability of an embryo reaching each of the outcomes was significantly higher in fast developing embryos compared with intermediate or slow growing cleavage stage embryos, as well as in younger compared with older aged patient age groups.

DISCUSSION

Our results demonstrated that early mitotic activity is an important marker of genomic competence. Rapid cleavage stage development not only predicted blastulation, but also euploidy as diagnosed by NGS. Patient age played a significant role in predicting outcomes, with patients from younger SART age groups having significantly greater odds of their embryos reaching the blastocyst stage, trophectoderm biopsy, and being euploid than patients from older SART age groups. Additionally, our study demonstrated that embryos that reach the blastocyst stage and are eligible for biopsy have an equal likelihood of being euploid. To our knowledge, this study is the first to utilize NGS for PGT-A to correlate chromosomal copy number with cleavage stage cell division.

Previous work has established the significance of cell count on day 3 as an important predictor of clinical outcomes (Racowsky et al., 2000). Our findings are in accordance with prior studies that have determined that slow growing cleavage stage embryos have reduced embryonic competence. However, our study counters many of the previous findings and governing body suggestions about blastocyst rate, biopsied blastocyst rate, and euploid rate for every increase in cell count, with a significant difference being our utilization of NGS for PGT-A. Importantly, prior work has demonstrated the improved sensitivity of NGS in detecting lower levels of mosaicism, segmental aneuploidies, and polyplody when compared to aCGH (Friedenthal et al., 2018; Werlin et al., 2017).

Studies utilizing morphokinetics via time-lapse technology have reported similar findings. Campbell et al. (2013) found that embryos that reached the compaction and blastulation stages faster were significantly more likely to be euploid than embryos that were delayed at either stage. Similarly, Petersen et al. (2016) developed an algorithm to predict blastocyst formation and quality based on morphokinetic data through day 3 of development. In their study, embryos that had ≥ 8 cells on day 3 of development were given a higher score than embryos with < 8 cells. Finally, using time-lapse technology and morphokinetic parameters, Minasi et al. (2016) found that the cleavage from three to four cells was significantly faster, the four-cell stage was reached significantly earlier, and blastocysts expanded and hatched significantly faster, in euploid compared with aneuploid blastocysts.

There were several strengths to our study. First, our study was performed at a single academic institution, with a team of uniformly trained embryologists. Second, our study is notable for its large sample size, which allows for greater accuracy and precision and provides more reliable and generalizable results. Last, all PGT-A was performed using NGS, the standard genetic platform for modern ART treatment centers.

| Table 2. Multivariable GEE Logistic Regression Models with Cleavage Stage Cohorts. |
|----------------------------------|-----------------|-----------------|-----------------|-----------------|
|                                  | Slow (N=6,153 embryos) | Intermediate (N=13,894 embryos) | Fast (N=19,254 embryos) |
|                                  | Adjusted OR (95% CI)* | Reference        | Adjusted OR (95% CI)* | p-value         |
| Blastulation Rate                | 0.28 (0.26, 0.30)    | 1.0             | 1.38 (1.29,1.48)     | <0.0001         |
| Biopsied Blastocyst Rate         | 0.25 (0.23, 0.28)    | 1.0             | 1.42 (1.34,1.51)     | <0.0001         |
| Euploid Rate                     | 0.93 (0.79, 1.08)    | 1.0             | 1.08 (1.01,1.17)     | 0.03            |

*Adjusted analyses were performed using a multivariable logistic generalized estimation equation (GEE) modeling adjusted embryo cell division speed at day 3 (cleavage stages: slow <6, intermediate 6-8, fast >8) accounting for within-correlation at the patient and cycle level, controlling for patient age, BMI, AMH, and percent embryo fragmentation.

The clinical potential of the cleavage stage embryos in their studies. Prior studies also had smaller sample sizes relative to the large sample size of our study. Additionally, as much of this work was performed several years prior to the current study, it must be recognized that significant changes have occurred in culture conditions, including changes in media (Sunde et al., 2016), improved laboratory circulation and incubation environments, and changes in oxygen tension which may have impacted their findings (Kirkegaard et al., 2013). Our laboratory implemented modern approaches to ART treatment and further strengthened to our findings. Finally, and importantly, prior studies utilized older platforms for chromosomal copy number analysis, generally either fluorescence in situ hybridization, SNP array, or aCGH, which are more limited in their ability to analyze the entire complement of chromosomes, to identify smaller deletions and duplications, and to detect mosaicism when compared with NGS.
Table 3. Multivariable GEE Logistic Regression Models with Cleavage Stage Embryo Cell Count.

| Variables                      | Blastulation | Blastocyst Biopsied | Euploid |
|-------------------------------|--------------|---------------------|---------|
|                               | Adj. OR (95% CI)* | p-value | Adj. OR (95% CI)* | p-value | Adj. OR (95% CI)* | p-value |
| Adjusted Day 3 Cell Count     | 1.29 (1.27, 1.32) | <0.0001 | 1.24 (1.22, 1.26) | <0.0001 | 1.02 (1.01, 1.04) | 0.007  |
| Fragmentation Percent         |              | <0.0001 |                    |         |                    |         |
| Low (<10%)                    | Reference    |          | Reference          |         | Reference          | 0.01    |
| Moderate (10-20%)             | 0.39 (0.37, 0.42) |          | 0.38 (0.35, 0.41) |         | 1.05 (0.93, 1.18) | 2.09 (1.26, 3.44) |
| High (>20%)                   | 0.15 (0.13, 0.18) |          | 0.10 (0.07, 0.13) |         |                    |         |
| Patient Age Group             |              | <0.0001 |                    |         | <0.0001            | <0.0001 |
| A (<35)                       | Reference    |          | Reference          |         | Reference          |         |
| B (35-37)                     | 1.01 (0.91, 1.13) |          | 0.95 (0.87, 1.04) |         | 0.79 (0.72, 0.87) |         |
| C (38-40)                     | 0.84 (0.76, 0.94) |          | 0.71 (0.64, 0.77) |         | 0.49 (0.44, 0.54) |         |
| D (41-42)                     | 0.65 (0.57, 0.75) |          | 0.44 (0.39, 0.50) |         | 0.25 (0.21, 0.30) |         |
| E (>42)                       | 0.54 (0.49, 0.60) |          | 0.31 (0.28, 0.34) |         | 0.15 (0.13, 0.18) |         |
| BMI                           | 1.00 (0.99, 1.01) | 0.55    | 0.99 (0.98, 1.00) | 0.03    | 1.01 (1.00, 1.02) | 0.12    |
| AMH                           | 1.06 (1.01, 1.11) | 0.03    | 0.96 (0.91, 1.00) | 0.09    | 1.05 (1.00, 1.10) | 0.02    |

*Adjusted analyses were performed using a multivariable logistic generalized estimation equation (GEE) modeling embryo cell division speed at day 3 accounting for within-correlation at the patient and cycle level, controlling for patient age, BMI, AMH, and percent embryo fragmentation.

This study is not without limitations. The retrospective study design can be subject to selection bias and the potential for confounding variables. Multivariable regression models were utilized to mitigate these effects and accounted for patients who underwent multiple cycles. Additionally, we recognize that the timing of the assessment of day 3 embryos can vary, and this may introduce bias. However, we computed the duration between the time of ICSI and the time of assessment on day 3 and utilized this data to create an adjusted cell count for each embryo, thereby minimizing the effect of this potential variable. Whether through time-lapse technology, non-invasive genomic, transcriptomic, or proteomic correlations, prospective studies should be performed to better delineate the predictive power of day 3 cell count and its relationship with embryonic euploidy.

In conclusion, in the largest study to date evaluating the association between cleavage stage embryo development and embryonic competence, our results demonstrated that cleavage stage embryos with ≥8 cells are more likely to become blastocysts and undergo trophectoderm biopsy than intermediate or slow day 3 embryos. Similar to others, we found that cleavage stage embryos with slow mitotic activity are less likely to develop to the blastocyst stage or undergo trophectoderm biopsy. Our data demonstrated that rapidly dividing cleavage stage embryos have high rates of euploidy and significant developmental potential and perform as well as, if not better than, intermediate or slow growing cleavage stage embryos. We believe that our findings may be applicable in the clinical setting and that patients may be reassured that fast cleaving embryos have a higher likelihood of blastulation and biopsy and equal likelihood of euploidy when compared to slower day 3 embryos. Future studies should aim to identify precise morphokinetic features that, combined with both genomic and non-genomic markers, create multi-dimensional predictive data to power decision support tools that predict...
Figure 2. Predicted Probability of Reaching Biopsy. Predicted probability of being biopsied for the number of cells at day 3 by oocyte age group, fixing BMI and AMH using the patient sample mean and fragmentation at <10%.

Figure 3. Predicted Probability of Being Euploid. Predicted probability of being euploid for the number of cells at day 3 by oocyte age group, fixing BMI and AMH using the patient sample mean and fragmentation at <10%.

implantation, optimize embryo selection, and improve patient outcomes.

ACKNOWLEDGEMENTS

The authors thank the physicians, fellows, embryologists, research and other staff members at the study site and affiliated hospital for their valuable work and help in contribution to the development of this manuscript.

CONFLICT OF INTEREST

The authors declare no conflict of interest.

Corresponding author:
Jenna Friedenthal
Department of Obstetrics, Gynecology, and Reproductive Science
Icahn School of Medicine at Mount Sinai
New York, NY 10029, USA.
E-mail: jenna.friedenthal@gmail.com

REFERENCES

Alikani M, Calderon G, Tomkin G, Garrisi J, Kokot M, Cohen J. Cleavage anomalies in early human embryos and survival after prolonged culture in-vitro. Hum Reprod. 2000;15:2634-43. PMID: 11098037 DOI: 10.1093/humrep/15.12.2634

Anderson AR, Wilkinson S, Price S, Crain JL. The relationship between early embryo cleavage and euploidy. Fertil Steril. 2004;82:96. DOI: 10.1016/j.fertnstert.2004.07.244
Bos-Mikich A, Mattos AL, Ferrari AN. Early cleavage of human embryos: an effective method for predicting successful IVF/ICSI outcome. Hum Reprod. 2001;16:2658-61. PMID: 11726591 DOI: 10.1093/humrep/16.12.2658

Campbell A, Fishel S, Bowman N, Duffy S, Sedler M, Hickman CF. Modelling a risk classification of aneuploidy in human embryos using non-invasive morphokinetics. Reprod Biomed Online. 2013;26:477-85. PMID: 23918033 DOI: 10.1016/j.rbmo.2013.02.006

Finn A, Scott L, O’Leary T, Davies D, Hill J. Sequential embryo scoring as a predictor of aneuploidy in poor-prognosis patients. Reprod Biomed Online. 2010;21:381-90. PMID: 20638336 DOI: 10.1016/j.rbmo.2010.05.004

Friedenthal J, Maxwell SM, Munné S, Kramer Y, McCulloh DH, McCaffrey C, Grifo JA. Next generation sequencing for preimplantation genetic screening improves pregnancy outcomes compared with array comparative genomic hybridization in single thawed euploid embryo transfer cycles. Fertil Steril. 2018;109:527-32. PMID: 29605407 DOI: 10.1016/j.fertnstert.2017.12.017

Hernandez-Nieto C, Lee JA, Slifkin R, Sandler B, Copperman AB, Flisser E. What is the reproductive potential of day 7 euploid embryos? Hum Reprod. 2019;34:1697-706. PMID: 31398251 DOI: 10.1093/humrep/dez129

Kirkegaard K, Hindkjær JJ, Ingerslev HJ. Effect of oxygen concentration on human embryo development evaluated by time-lapse monitoring. Fertil Steril. 2013;99:738-44.e4. PMID: 23245683 DOI: 10.1016/j.fertnstert.2012.11.028

Lee MJ, Lee RK, Lin MH, Hwu YM. Cleavage speed and implantation potential of early-cleavage embryos in IVF or ICSI cycles. J Assist Reprod Genet. 2012;29:745-50. PMID: 22825967 DOI: 10.1007/s10815-012-9777-z

Luna M, Copperman AB, Duke M, Ezcurra D, Sandler B, Barritt J. Human blastocyst morphological quality is significantly improved in embryos classified as fast on day 3 (>or=10 cells), bringing into question current embryological dogma. Fertil Steril. 2008;89:358-63. PMID: 17531231 DOI: 10.1016/j.fertnstert.2007.03.030

Magli MC, Gianaroli L, Munné S, Ferraretti AP. Incidence of chromosomal abnormalities from a morphologically normal cohort of embryos in poor-prognosis patients. J Assist Reprod Genet. 1998;15:297-301. PMID: 9604763 DOI: 10.1023/A:1022596528036

Magli MC, Gianaroli L, Ferraretti AP, Lippi M, Ruberti A, Farfalli V. Embryo morphology and development are dependent on the chromosomal complement. Fertil Steril. 2007;87:534-41. PMID: 17123520 DOI: 10.1016/j.fertnstert.2006.07.1512

Maxwell SM, Collins P, Hodes-Wertz B, McCulloh DH, McCaffrey C, Wells D, Munné S, Grifo JA. Why do euploid embryos miscarry? A case-control study comparing the rate of aneuploidy within presumed euploid embryos that resulted in miscarriage or live birth using next-generation sequencing. Fertil Steril. 2016;106:1414-9.e5. PMID: 27692437 DOI: 10.1016/j.fertnstert.2016.08.017

Minasi MG, Colasante A, Riccio T, Ruberti A, Casciani V, Scarselli F, Spinella F, Fiorentino F, Varricchio MT, Greco E. Correlation between aneuploidy, standard morphology evaluation and morphokinetic development in 1730 biopsied blastocysts: a consecutive case series study. Hum Reprod. 2016;31:2245-54. PMID: 27591227 DOI: 10.1093/humrep/dew183

Munné S, Wells D. Detection of mosaicism at blastocyst stage with the use of high-resolution next-generation sequencing. Fertil Steril. 2017;107:1085-91. PMID: 28390692 DOI: 10.1016/j.fertnstert.2017.03.024

Petersen BM, Boel M, Montag M, Gardner DK. Development of a generally applicable morphokinetic algorithm capable of predicting the implantation potential of embryos transferred on Day 3. Hum Reprod. 2016;31:2231-44. PMID: 27609980 DOI: 10.1093/humrep/dew188

Petracchi F, Colaci DS, Igarzabal L, Gadow E. Cytogenetic analysis of first trimester pregnancy loss. Int J Gynaecol Obstet. 2009;104:243-4. PMID: 19036372 DOI: 10.1016/j.ijgo.2008.10.014

Pons MC, Carrasco B, Parriego M, Boada M, González-Foruria I, Garcia S, Coroleu B, Barri PN, Veiga A. Deconstructing the myth of poor prognosis for fast-cleaving embryos on day 3. Is it time to change the consensus? J Assist Reprod Genet. 2019;36:2299-305. PMID: 31478159 DOI: 10.1007/s10815-019-01574-y

Racowsky C, Jackson KV, Cekleniak NA, Fox JH, Hornstein MD, Ginsburg ES. The number of eight-cell embryos is a key determinant for selecting day 3 or day 5 transfer. Fertil Steril. 2000;73:558-64. PMID: 10689013 DOI: 10.1016/S0015-0282(99)00565-8

Scott RT Jr, Upham KM, Forman EJ, Zhao T, Treff NR. Cleavage-stage biopsy significantly impairs human embryonic implantation potential while blastocyst biopsy does not: a randomized and paired clinical trial. Fertil Steril. 2013;100:624-30. PMID: 23773313 DOI: 10.1016/j.fertnstert.2013.04.039

Sekhon L, Lee JA, Flisser E, Copperman AB, Stein D. Blastocyst vitrification, cryostorage and warming does not affect live birth rate, infant birth weight or timing of delivery. Reprod Biomed Online. 2018;37:33-42. PMID: 29706285 DOI: 10.1016/j.rbmo.2018.03.023

Sunde A, Brison D, Dumoulin J, Harper J, Lundin K, Magli MC, Van den Abbeel E, Veiga A. Time to take human embryo culture seriously. Hum Reprod. 2016;31:2174-82. PMID: 27554442 DOI: 10.1093/humrep/dew157

Werlin LB, Emeny-Smith K, Martorana K, Nass T. Next generation sequencing (NGS) vs Array CGH (ACGH) for all embryos? Fertil Steril. 2017;107:e48. DOI: 10.1016/j.fertnstert.2017.02.093